ライフサイエンスコーパス: Bayer

1 COG-ACRIN Cancer Research Group, Pfizer, and Bayer.

2 C virus genotyping methodologies supplied by Bayer, Abbott, and Third Wave Technologies.

3 Bayer and Agouron have discontinued their ongoing Phase

4 nd incorporates branched DNA technology from Bayer and luminometer-based readings of a chemilumigenic

5 Abbott assay measure = 0.032 + 1.01 log(10) Bayer assay measure.

6 .0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantifie

7 2 log10 greater than those obtained with the Bayer bDNA assay for genotype 1, 2, and 3 samples.

8 61 to 0.96 log10 greater than the values for Bayer bDNA assay for samples with genotype 1, 2, or 3 sa

9 Roche Monitor and Bayer bDNA detected 27 out of 28 and 13 out of 28 replic

10 Bayer bDNA was the most reproducible of the four assays.

11 che Monitor), and Bayer VERSANT HCV RNA 3.0 (Bayer bDNA) assays.

12 s genotypes (1 through 4) were tested in the Bayer bDNA, Abbott RT-PCR, and Roche RT-PCR assays.

13 Bayer bDNA-negative specimens were tested reflexively us

14 n average, 0.15 log10 lower than that of the Bayer bDNA.

15 using the known transmission spectra of the Bayer color filters.

16 pixels of different channels (R, G, B) on a Bayer color sensor are not at the same physical location

17 the imaging process by a factor of three, a Bayer color sensor-chip can also be used to demultiplex

18 ith a commercial genotyping assay (Tru Gene; Bayer Corp.) were analyzed to assess the utility of thes

19 dization line probe assay (INNO-LiPA HCV II; Bayer Corp., Tarrytown, N.Y.) for genotyping of hepatiti

20 European Union, Cancer Research UK, Bayer Corporation, National Starch and Chemical Co, UK M

21 European Union; Cancer Research UK; Bayer Corporation; National Starch and Chemical Co; UK M

22 ide urine ACR was measured by nurses using a Bayer DCA 2000 analyzer and expressed in mg/mmol (refere

23 recision, and excellent correlation with the Bayer Diagnostics VERSANT HBV DNA 3.0 (branched DNA) ass

24 HCV RNA 2.0 branched-chain DNA (bDNA) assay (Bayer Diagnostics) for hepatitis C viral load determinat

25 ation, the VERSANT HCV RNA 3.0 Assay (bDNA) (Bayer Diagnostics, Tarrytown, N.Y.) was shown to have ex

26 th recognized by the Advia Centaur BNP test (Bayer Diagnostics, Tarrytown, New York), but only recomb

27 ell Host & Microbe, Lazear et al. (2016) and Bayer et al. (2016) show that innate immunity can restri

28 t of hepatitis C virus (HCV) RNA levels, the Bayer HCV RNA (version 3.0) branched DNA assay and the A

29 Janssen Research & Development and Bayer HealthCare AG.

30 CV and the VERSANT HCV RNA 3.0 assay (bDNA) (Bayer HealthCare LLC) among a group of 93 clinical speci

31 ive by the VERSANT HCV RNA qualitative test (Bayer HealthCare LLC, Tarrytown, N.Y.).

32 HBV ASR and VERSANT HBV DNA 3.0 assay (bDNA; Bayer HealthCare LLC, Tarrytown, NY) results among clini

33 d from the TRUGENE HCV 5' NC Genotyping Kit (Bayer HealthCare LLC, Tarrytown, NY), used in conjunctio

34 Bayer HealthCare Pharmaceuticals and Janssen Research &

35 Bayer HealthCare Pharmaceuticals and Janssen Research &

36 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceutical

37 Algeta and Bayer HealthCare Pharmaceuticals.

38 Novo Nordisk, Bayer HealthCare, [corrected] and Pfizer.

39 VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizu

40 (MR) imaging with gadoxetic acid (Primovist; Bayer Healthcare, Whippany, NJ) was performed.

41 sted hazard ratio (HR) (95% CI) for Kogenate Bayer/Helixate NexGen compared with Advate was 2.14 (1.1

42 Of 128 patients treated with Kogenate Bayer/Helixate NexGen, 45 (35.2%, 95% confidence interva

43 e determined for 136 of 137 specimens by the Bayer method, 121 of 137 specimens by the Invader assay,

44 nsive Clinical Trials Unit at UCL, LUPUS UK, Bayer, National Institute for Health Research Biomedical

45 The second generation Hoechst-Bayer non-nucleoside inhibitor, HBY 097 (S-4-isopropoxyc

46 National Cancer Institute, Bayer Oy (formerly Schering Oy).

47 tomatic, and gadolinium-enhanced (Magnevist; Bayer Pharma, Berlin, Germany) magnetic resonance (MR) i

48 ish Cancer Foundation, SIAK Switzerland, and Bayer Pharma.

49 Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma.

50 AMPLICOR HIV-1 MONITOR test version 1.0, the Bayer Quantiplex HIV RNA 3.0 assay, or a QC-RT-PCR metho

51 rcially available ultrasensitive assays, the Bayer Quantiplex HIV-1 bDNA version 3.0 (bDNA 3.0) assay

52 In this issue of Cell Host & Microbe, Bayer-Santos et al. (2016) show that the Salmonella effe

53 Northern Ireland, Biogen Idec, Merck Serono, Bayer Schering Pharmaceuticals, Teva Pharmaceuticals Ind

54 Bayer TMA detected all seven replicates with 1.0 log10 I

55 the Bayer VERSANT HCV RNA qualitative assay (Bayer TMA).

56 The Bayer transcription-mediated amplification (TMA) and the

57 We evaluated the Bayer TRUGENE HIV-1 genotyping (TG) assay using prospect

58 he multikinase inhibitor sorafenib (Nexavar, Bayer), used in the treatment of renal and hepatocellula

59 TaqMan Analyte-Specific Reagent (TaqMan) and Bayer Versant HCV bDNA 3.0 assay.

60 mplicor Monitor HCV 2.0 (Roche Monitor), and Bayer VERSANT HCV RNA 3.0 (Bayer bDNA) assays.

61 ell with HCV viral load as determined by the Bayer VERSANT HCV RNA 3.0 bDNA assay.

62 Stored specimens were tested using the Bayer VERSANT HCV RNA Qualitative (TMA) Assay (LOD 9.6 I

63 specimens were tested reflexively using the Bayer VERSANT HCV RNA qualitative assay (Bayer TMA).

64 Roche COBAS Amplicor and Bayer VERSANT HCV RNA qualitative assays were used.

65 was evaluated in the CAP/CTM, Amplicor, and Bayer Versant HIV-1 bDNA 3.0 (Versant) assays using a co

66 Abbott LCx HIV RNA Quantitative assay (LCx), Bayer Versant HIV-1 RNA 3.0 (bDNA), Roche AMPLICOR HIV-1

67 erally agreed with the results of the B-DNA (Bayer) viral load assays.